Abstract: The invention relates to a composition for improving the syndrome of diabetes and complication thereof. The composition comprises an effective amount of Lactobacillus strain which is at least one selected from the group consisting of: Lactobacillus reuteri GMNL-89 strain, Lactobacillus gasseri GMNL-205 strain, Lactobacillus reuteri GMNL-263 strain and a pharmaceutical acceptable vehicle. The Lactobacillus gasseri GMNL-205 strain and Lactobacillus reuteri GMNL-263 strain are novel isolated Lactobacillus strains. In addition, the invention also relates to a novel use of the composition or the Lactobacillus strains for improving the syndrome of diabetes and complication thereof.

Abstract: Compositions are described which contain lactoferrin and angiogenin. The described compositions are useful in treatment of a variety of conditions, particularly in promoting bone health and relief of menopausal symptoms.

Abstract: This invention relates to methods for inhibiting growth of anaerobic bacteria, particularly halitosis causing bacteria. The methods use BLIS-producing Streptococcus salivarius strains, extracts thereof, and compositions comprising same in the prevention or treatment of halitosis.

Abstract: The invention relates to a composition comprising a combination of an elder extract (Sambucus nigra) and a strain of L. paracasei, L. casei, L. bulgaricus or S. thermophilus, intended for stimulating immunity and/or promoting an anti-infectious and/or anti-inflammatory response.

Abstract: The present invention is a grain product. The grain product includes a first fraction including bran. The first fraction is milled to a first particle size of less than 500 micrometers. The grain product also includes a second fraction including germ. The second fraction is milled to a second particle size of less than 500 micrometers. The grain product is at least one of: a food product, a nutritional supplement, a dietary supplement, a fiber supplement, a digestive supplement, a functional food, and a medical food.

Abstract: A composition comprising at least one isoflavone, phloridzin and one or more probiotics. A composition as described herein is also provided for internal use as a natural alternative to hormone replacement therapy and for treating disorders such as menopause and correlated symptoms, alcoholism, stress, insomnia, obesity and cellulite.

Abstract: The present invention relates to compositions for use in low-birth weight infants. In particular, the compositions are probiotic compositions which are used for achieving full enteral feeding in low birth weight infants. The invention is also concerned with the use of specific probiotics in the manufacture of low-birth weight infant formulations.

Abstract: The disclosure provides an oral composition for reducing serum cholesterol, serum lipids, body fat, or atherogenic index or for prophylaxis or treatment of atherosclerosis, cardiovascular or cerebrovascular diseases, comprising a highly bsh active bacteria, isolate or supernatant thereof; wherein the highly bsh active bacteria degrades >50 ?mol glycodeoxycholic acid (GDCA)/gram/hour and >2 ?mol taurodeoxycholic acid (TDCA)/gram/hour when measured over 1 hour and 5 hours, respectively, or degrades >65 ?mol GDCA/g/hr and >7 ?mol TDCA/g/hr when measured over 30 minutes.

Abstract: Compositions and methods for improving renal function with Streptococcus probiotic bacteria selected for converting nitrogenous waste into non-toxic compounds in vivo are provided. By reducing the levels of nitrogenous wastes, the instant compositions reduce kidney burden.

Abstract: The use of a Lactobacillus casei strain for improving the resistance of a tobacco user against a common infectious disease, especially against a respiratory common infectious disease, and for improving the cellular immune response of an individual in case of respiratory common infectious disease.

Abstract: Methods to reduce or inhibit populations of pathogenic bacteria in animals are disclosed. These methods include providing a number of administrations of probiotic microorganism compositions containing one or more strains or species of probiotic microorganisms. Routes of administration, dosage of administration and pathogenic organisms to be reduced or inhibited are also disclosed.

Abstract: The present invention relates to compositions to be administered to infants delivered via caesarean section and in particular to a product comprising inactivated cells and/or bacterial cell fragments of Gram-negative bacteria and of optionally inactivated Gram-positive bacteria. Thereby it is possible to stimulate a fast colonisation of the intestinal microbiota of said infants.

Abstract: The present invention relates to a pharmaceutical composition for controlled delivery of at least one active ingredient into an aqueous phase, said pharmaceutical composition comprising: a tablet, preferably obtainable by compression, said tablet comprising said at least one active ingredient and optionally excipients; and a coating, applied on said tablet, said coating covering at least part of said tablet to impede the release of said at least one active ingredient from at least part of the surface of said tablet, said coating being applied in a manner allowing the release of said at least one active ingredient from said tablet after contacting said pharmaceutical composition with said aqueous phase, establishing one or more degradation surfaces of said tablet; wherein the first derivative of the area of each degradation surface with respect to time is larger than or equal to zero.

Abstract: Strains of bacteria characterized by exhibiting: (a) a 7?-dehydroxylase activity of less than 50%, and (b) a bile acid deconjugation activity of less than 50%, and descendants, mutants and derivatives thereof preserving activities (a) and (b); and a pharmaceutical composition using one or more of such strains and use of same for preventing and treating diseases associated with or caused by an altered metabolism of bile acids.

Abstract: The present invention relates to a method for decreasing borboiygmi in a subject by administering a probiotic, preferably a bacteria of the Bifidobacterium genus, said method being on one aspect of the invention a non therapeutic method.

Abstract: The present invention relates to supporting weight management, weight loss and/or to the prevention and/or treatment of metabolic disorders. In particular the present invention relates to preventing and/or treating metabolic disorders by modulating, in particular reducing the amount of proteobacteria and/or deferribacteres in the gut. One embodiment of the present invention relates to the use of a primary composition comprising an agent that reduces the amount of proteobacteria, preferably gamma-proteobacteria, even more preferred enterobacteria; and/or deferribacteres in the gut for the preparation of a composition to treat or prevent metabolic disorders, to support weight loss and/or to support weight management.

Abstract: A nutritional composition for administration to an infant which composition comprises, on a dry matter basis, from 2.5 to 15.0 wt % of an oligosaccharide mixture consisting of N-acetylated oligosaccharide(s), galacto-oligosaccharide(s) and sialylated oligosaccharide(s) with the proviso that the composition comprises at least 0.02 wt % of an N-acetylated oligosaccharide, at least 2.0 wt % of a galacto-oligosaccharide and at least 0.04 wt % of a sialylated oligosaccharide and that the N-acetylated oligosaccharide(s) comprise 0.5 to 4.0% of the oligosaccharide mixture, the galacto-oligosaccharide(s) comprise 92.0 to 98.5% of the oligosaccharide mixture and the sialylated oligosaccharide(s) comprise 1.0 to 4.0% of the oligosaccharide mixture. The composition is useful for administration to an infant in the first six months of life to reduce the risk of obesity later in life.

Abstract: The present invention relates to the use of bacteria of the species Streptococcus phocae for the manufacture of a vaccine, to methods for the production of such vaccines, to bacteria of the species Streptococcus phocae for use in a vaccine and to methods for the combating of Streptococcus phocae infection in fish.

Abstract: This invention provides a composition comprising a daidzein-containing substrate and a strain of micro-organism capable of metabolizing daidzein to equol as essential ingredients. This composition is effective in the prevention and alleviation of unidentified clinical syndrome inclusive of menopausal syndrome in middle-aged to elderly women for which no effective means of prevention or alleviation has heretofore been available.

Abstract: A novel lactic acid bacterium strain is found, which has a high IgA production-inducing ability and a high immunostimulating activity, and belongs to the genus Enterococcus. Thus, provided is an excellent lactic acid bacterium preparation for foods or feeds, which has a high enteric colonization rate. Specifically disclosed are: a novel lactic acid bacterium Enterococcus faecium NHRD IHARA (FERM BP-11090) which has a high IgA production-inducing ability and a high immunostimulating activity; and a lactic acid bacterium preparation for enhancing the production of immunoglobulin A, which comprises a culture of the bacterium strain, an extract of the bacterium strain, or a product of any treatment of cells of the bacterium strain.

Abstract: The present disclosure provides a device having a casing with a barrier surface and a contact surface and a composition in the casing having a nitric oxide precursor and an isolated enzyme or live cell expressing an endogenous enzyme, for converting the nitric oxide gas precursor to nitric oxide gas or having activity on a substrate that produces a catalyst that causes the conversion of the nitric oxide gas precursor to nitric oxide gas. The present disclosure also provides compositions, methods and uses for skin cosmesis.

Abstract: The invention provides compositions comprising one or more isolated LDH-deficient mutans streptococcus strains and one or more isolated S. oralis strains and/or one or more isolated S. uberis strains. Compositions of the invention are useful to maintain oral health, by for example treating and/or preventing one or more symptoms of dental caries, periodontitis and/or other oral cavity diseases or wounds.

Abstract: Compositions, methods, etc., comprising Pediococcus and at least one other probiotic microbial organism that reduce one or more symptoms of an autism spectrum disorder such as autism. The compositions can be used, for example, as dietary supplements, food additives, and pharmaceutical preparations.

Abstract: The present invention is a method for preventing or treating an immune-relevant disease by modulating commensal microbiota populations via antibiotics, exogenous microbiota and/or probiotics.

Abstract: This invention pertains to a method of promoting gastrointestinal health by ingesting a composition comprising one or more probiotic microorganisms, one or more carbohydrate sources, and one or more resistant protein products. Large intestinal health is benefited by one or more of the following: increased fecal weight, lower fecal pH, increased carbohydrate fermentation, and amelioration of protein fermentation.

Abstract: The method for increasing lactose tolerance in subjects exhibiting lactose intolerance symptoms implements a protocol where the subjects ingest a gradually increasing amount of lactose containing product over a six week period. At various points during the six week period the subject ingests the lactose containing product once a day and then twice a day. The lactose containing product can be in liquid form, such as for example, milk, and is preferably in a powder form which is taken either by ingesting capsules having the lactose powder or in a granular form mixed with water or other non-lactose containing liquid. At the end of the six week period, the subject's tolerance for lactose containing products is substantially increased, with the potential of eliminating the subject's lactose intolerant behavior indefinitely.

Abstract: The invention relates to the use of probiotics in the manufacture of a composition for enhancing a metabolic profile in a subject. The probiotics are capable of preventing and treating diseases or disorders associated with an abnormal metabolic profile, especially a lipid profile by normalizing the profile. The probiotics are particularly effective in down-regulating levels of lysophosphatiydylcholines (LysoPCs) and ceramides.

Abstract: A composition to be used as a natural preservative is provided. The composition comprises 1.0 to 20% w/w one or more naturally occurring substances containing salicylate, 0.1 to 20% w/w one or more species of lonicera, 0.1 to 80% w/w one or more leuconostoc, and 0.1 to 10% w/w gluconic acid. The composition has antimicrobial properties and is in a liquid form.

Abstract: The present invention relates to a use of an effective amount of at least one probiotic microorganism and/or a fraction thereof and/or a metabolite thereof for preventing and/or treating dandruff disorders of the scalp, as well as a cosmetic process for preventing and/or treating a dandruff condition including the administration a first cosmetic active agent and of at least a second cosmetic active agent, topically, the said first and second cosmetic active agents being formulated in separate compositions, the first cosmetic active agent being chosen from probiotic microorganisms, and mixtures thereof, and the second cosmetic active agent being chosen from antidandruff active agents.

Abstract: The invention relates to a composition comprising revivable dehydrated micro-organisms. The invention is characterised in that it further comprises particles at least 50% of which have a mean diameter greater than 250 ?m. The invention is applicable, in particular, to human or veterinary pharmaceuticals, to dietetics or to food products.

Abstract: The present invention relates in general to medium chain dicarboxylic acids, their derivatives and their uses. In particular, the present invention relates to a composition comprising medium chain dicarboxylic acids and to the use of medium chain dicarboxylic acids and their derivatives for the preparation of products to treat or prevent metabolic disorders. The composition of the present invention can particularly well be used to treat or prevent hyperglycemia, for example diabetes.

Abstract: A method of modulating the microbial balance of the digestive ecosystem in a mammal comprising administering to a mammal in need thereof a composition comprising at least one nonpathogenic, hydrogenotrophic, acetogenic bacterial strain, along with a pharmaceutical and related methods, are described.

Abstract: A nutritional composition for reducing oxidative damage and lipid peroxidation in humans, while allowing for the oxidative reactions necessary to sustain vital biological functions. The nutritional compositions comprise adaptogens comprising astragalus root, ashwagandha root, cordyceps, holy basil leaf, maca root, reishi mushrooms, schizandra, and suma root; superfoods comprising acerola, camu-camu, pomegranate, bilberry, blueberry, Goji berries, Acai, maitake, citrus bioflavonoids, rose hips, and Gingko biloba; probiotics comprising bifidobacterium longum, lactobacillus acidophilus, lactobacillus acidophilus DDS-1, lactobacillus bulgaricus, lactobacillus casei, and streptococcus thermophilus; and enzymes comprising amylase, papain, cellulose, lactase, lipase, protease, and bromelain. The nutritional compositions may also be provided as a meal replacement and further comprise one or more plant products, algae, vitamins, minerals, protein and MSM.

Abstract: The invention provides an anti-wrinkle agent which has an excellent effect of inhibiting the formation of wrinkles and excellent safeness. The anti-wrinkle agent contains, as an active ingredient, a culture supernatant of a lactic acid bacterium belonging to Streptococcus thermophilus.

Abstract: Compositions for improving the health of a subject comprise alpha-(1,2)-branched alpha-(1,6) oligodextrans, preferably with an average molecular weight between about 10 kDa and 70 kDa, between about 10% and 50% alpha-(1,2)-osidic side chains, and having at least partial indigestibility in the subject. Methods for improving the health of a subject comprise administering the composition to a subject in an amount effective to improve gut health, or to prevent or treat a gastrointestinal disorder, a cholesterol-related disorder, diabetes, or obesity. Methods for making oligodextrans having controlled size and controlled degree of branching comprise providing alpha-(1,6) oligodextrans having an average molecular weight between 0.5 and 100 kDa and introducing at least 10% alpha-(1,2)-osidic side chains onto the alpha-(1,6) oligodextrans.

Abstract: The current invention provides use of a CLA-producing bacterium for the in vivo conversion in the gut of polyunsaturated fatty acids to CLA. The CLA-producing bacterium is selected from one or more of the group consisting of propionibacteria, lactobacilli, lactococci and streptococci, and bifidobacteria.

Abstract: The invention relates to a composition and method of manufacture including a substrate coated with a biopolymer and aqueous biological gel and subsequently coated with at least one desiccation agent. The resulting composition is dry to touch, has a low water activity and stabilises the biological material for storage over at least one month at ambient temperatures.

Abstract: The present disclosure provides embodiments of a method for characterizing microbial populations. Exemplified by methods for characterizing microbiota in vaginal samples, the methods provided herein are widely applicable to the characterization of microbial communities. Also provided are probiotic regimens and methods for selecting appropriate probiotic regimens based on the normal vaginal microbiota of a subject. Reagents and kits for detecting normal vaginal microbiota and diagnosing pathogenic microorganisms in the vagina are also provided.

Abstract: The invention relates to Streptococcus suis infection in pigs, vaccines directed against those infections and tests for diagnosing Streptococcus suis infections. The invention provides an isolated or recombinant nucleic acid encoding a capsular gene cluster of Streptococcus suis or a gene or gene fragment derived thereof. The invention further provides a nucleic acid probe or primer allowing species or serotype-specific detection of Streptococcus suis. The invention also provides a Streptococcus suis antigen and vaccine derived thereof.

Abstract: The invention provides compositions, kits, and methods for providing or restoring beneficial bacteria to a subject. The compositions and kits optionally include food or nutrients to promote growth and proliferation of the bacteria in the subject or an antimicrobial agent to reduce the presence of undesirable or pathogenic microbes in the subject.

Abstract: A probiotic composition including the bacilli (1) Bacillus subtilis, (2) Bacillus coagulans, and (3) Enterococcus faecium. The composition may further include a carrier medium, such as fructo-oligo-saccharides (FOS), as incorporated in a dose form such as a pill, capsule, powder or sachet. The compositions of the invention may be usefully employed as health or nutritional supplements, food additives, or therapeutic agents for combating a wide variety of physiological disorders, such as irritable bowel syndrome, autism, and fibromyalgia.

Abstract: Described are strains including Enterococcus faecium strain 8G-1 (NRRL B-50173), Enterococcus faecium strain 8G-73 (NRRL B-50172), Bacillus pumilus strain 8G-134 (NRRL B-50174) and strains having all of the identifying characteristics of each of these strains. One or more of the strains can be used to treat or prevent acidosis. They can also be used to improve other measures of ruminant health and/or performance. Methods of using the strains, alone and in combination, are described. Methods of making the strains are also provided.

Abstract: The present application relates to a probiotic composition comprising a probiotic bacteria. The composition is particularly useful as a food supplement for normalizing the gastro-intestinal flora. The probiotic bacteria present in the composition contain species of Propionibacterium, Lactobacillus, Bifidobacterium and Streptococcus. Also disclosed herein are methods of producing such composition and uses of the composition.

Abstract: One embodiment of the present invention is directed to the use of a novel competitive exclusion bacterial composition to prevent or reduce Salmonella or Campylobacter colonization in poultry.

Abstract: It is intended to provide a safe composition for treating a disease or condition relating to autonomic nervous activity which has an autonomic nervous control effect; in particular, an effect of enhancing parasympathetic nervous activity. Thus, a medicinal composition, a food or a drink containing L-phenyl lactic acid and/or D-phenyl lactic acid and having an autonomic nervous control effect is provided.

Abstract: The present invention is directed to a wound or tissue dressing comprising a bacteria having the property of producing lactic acid from sugars by fermentation of the sugars. The bacteria preferably belongs to the family of lactic acid bacteria. The family of lactic acid bacteria refers to any bacteria belonging to a genus selected from the group consisting of Carnobacterium, Enterococcus, Lactobacillus, Lactococcus, Leuconostoc, Oenococcus, Pediococcus, Streptococcus, Tetragenococcus, Vagococcus and Weissella. There is also provided a wound or tissue dressing comprising an absorbent compound for absorbing wound exudate, wherein said wound or tissue dressing is attached to or comprises a lactic acid bacterium.

Abstract: A method of treating irritable bowel syndrome using a probiotic composition including the bacilli (1) Bacillus subtilis, (2) Bacillus coagulans, and (3) Enterococcus faecium. The composition may further include a carrier medium, such as fructo-oligo-saccharides (FOS), as incorporated in a dose form such as a pill, capsule, powder or sachet. The compositions of the invention may be usefully employed as health or nutritional supplements, food additives, or therapeutic agents for combating a wide variety of physiological disorders.

Abstract: The present invention relates generally to the field of nutrition, more particularly to the use of probiotics in nutrition. In particular the present invention relates to the use of a probiotic or of a mixture of probiotics in the manufacture of a nutritional composition or a medicament to act the colon in a pre- or post surgical environment.

Abstract: The present invention relates to a composition for the administration of biologically active substances in a gynaecologic and rectal ambit, as well as the uses of said composition. Said composition presents particularly favourable technological and stability characteristics of the end product, above all with regard to the viscosity after the dissolution/resuspension of the same in a hydrophilic liquid medium which allows a better adhesion and a direct contact from bacteria to the treated mucosae. Said composition includes a specific viscosizing agent selected from the group of the gums, which can play an important prebiotic function by contributing in a significant way to the correct growth and colonization of the probiotic culture, thus forming a perfect symbiotic system.

Abstract: Strains of bacteria characterized by exhibiting: (a) a 7?-dehydroxylase activity of less than 50%, and (b) bile acid deconjugation activity of less than 50%, and descendants, mutants and derivatives thereof preserving activities (a) and (b); and a pharmaceutical composition using one or more of such strains and use of same for preventing and treating diseases associated with or caused by an altered metabolism of bile acids.